Congenital disorder of glycosylation caused by mutation in DPM1 is a very rare inherited metabolic disease. It is usually called DPM1-CDG. In this condition, the body cannot add some sugar parts to proteins and fats in the normal way. This sugar-adding process is called glycosylation. Glycosylation is important because it helps many proteins fold correctly, move to the right place, and do their jobs in the brain, muscles, eyes, nerves, liver, gut, and many other organs. When both copies of the DPM1 gene do not work well, the body makes too little dolichol-phosphate-mannose, an important sugar donor, and this leads to a multisystem disease that often starts in infancy. [1] [2]
DPM1-CDG is a very rare inherited metabolic disease. It happens when both copies of the DPM1 gene do not work properly. The DPM1 gene helps the body make dolichol-phosphate mannose, a small but very important molecule used to build and attach sugar chains to proteins. These sugar chains help many proteins fold, travel, and work the right way. When this step is faulty, many organs can be affected, especially the brain, nerves, muscles, eyes, and gut. DPM1-CDG is usually autosomal recessive, which means a child gets one changed gene from each parent. [GeneReviews] [Orphanet]
People with DPM1-CDG often have global developmental delay, low muscle tone, seizures, microcephaly, eye problems, feeding trouble, and sometimes severe stomach or bowel symptoms. Some reported patients also had muscle disease, raised creatine kinase, or a congenital muscular dystrophy-like picture. Severity is variable. Some children are very severely affected in infancy, while a few reported people had milder disease. At present, there is no proven disease-specific cure for DPM1-CDG, so treatment is mainly supportive and guided by symptoms. [Orphanet] [CDG review] [case reports]
Another names
Other names used for this condition include DPM1-CDG, CDG-Ie, and congenital disorder of glycosylation due to DPM1 deficiency. It belongs to the broader family of congenital disorders of glycosylation (CDG) and is usually grouped under disorders of multiple glycosylation pathways and dolichol metabolism disorders. In simple words, it is not many separate diseases with many formal subtypes; instead, doctors usually describe it by severity, such as severe infantile presentation, neurologic-predominant presentation, or multisystem presentation, because the exact symptoms can vary from child to child.
Types
This condition does not have many formal subtype names like some common diseases do. In practice, doctors usually describe it by severity and body systems involved. A severe infantile neurologic type can include early seizures, marked low muscle tone, very poor development, and microcephaly. A milder neurologic type can show developmental delay, eye problems, and cerebellar dysfunction with less dramatic early illness. A muscle-dominant or dystroglycanopathy-like type can show congenital muscular dystrophy features. A multisystem type can include gut, liver, kidney, nerve, and eye problems together. These are clinical patterns, not separate official diseases. [5] [6] [7]
The DPM1 gene gives instructions for making the catalytic part of the dolichol-phosphate-mannose synthase complex. This complex helps produce Dol-P-Man, a sugar donor used in several important pathways, including N-glycosylation, O-mannosylation, and GPI-anchor formation. When DPM1 does not work properly, many proteins are not glycosylated in the right way. That is why one small gene problem can cause many symptoms in many organs at the same time. [8] [9]
DPM1-CDG is usually inherited in an autosomal recessive way. This means the child receives one nonworking copy of the gene from the mother and one nonworking copy from the father. The parents are often healthy carriers because one working copy is enough for them. The disease appears when both copies are affected. This is the main true cause of the disorder. [10] [11]
Causes
The strict medical truth is that the main cause is biallelic pathogenic variants in DPM1. Still, doctors and families often ask in what different ways this can happen. The following 20 items are different genetic cause patterns or disease-causing mechanisms linked to DPM1-CDG, not 20 unrelated diseases. [12] [13]
1. Homozygous pathogenic variant. The child inherits the same harmful DPM1 change from both parents. This is a classic cause in recessive disease. [14]
2. Compound heterozygous variants. The child inherits two different harmful DPM1 variants, one on each copy of the gene. This is also a common recessive pattern. [15] [16]
3. Missense variant. One DNA letter change can switch one amino acid in the DPM1 protein and reduce enzyme function. Some patients with milder disease have had this type of change. [17]
4. Small deletion. A tiny loss of DNA letters can remove an amino acid or shift the reading frame, making the protein unstable or very short. [18] [19]
5. Frameshift variant. A deletion or insertion can shift the gene code and usually leads to a badly damaged protein. [20]
6. Start-loss variant. If the first start signal of the gene is damaged, the protein may not be made correctly. A severe case report described this type of change. [21]
7. In-frame deletion. A small deletion may remove one amino acid without shifting the reading frame, but the enzyme can still lose function if that amino acid is important. [22]
8. Catalytic-site damage. A variant in a functionally important part of the DPM1 protein can directly lower enzyme activity. [23] [24]
9. Protein instability. Some variants may allow the protein to be made but cause it to fold badly and break down faster. [25]
10. Reduced enzyme amount. Fibroblast studies in affected patients have shown markedly reduced DPM1 activity, meaning the cell has too little working enzyme. [26]
11. Impaired Dol-P-Man production. Harmful DPM1 variants reduce the production of dolichol-phosphate-mannose, the key sugar donor. [27] [28]
12. Defective N-glycan assembly. Because Dol-P-Man is low, N-glycosylation in the endoplasmic reticulum is disturbed. [29] [30]
13. Defective O-mannosylation. DPM1 pathway failure can also disturb O-mannosylation, which helps explain muscle and brain involvement in some patients. [31]
14. Defective GPI-anchor formation. Lack of Dol-P-Man can impair proper surface expression of GPI-anchored proteins. [32]
15. Loss of function in both gene copies. The common final disease mechanism is that neither DPM1 copy works enough to meet body needs. [33] [34]
16. Pathogenic variant inherited from carrier parents. This family pattern is a direct cause in many affected children. [35]
17. Rare founder or recurrent variant. Some variants, like recurrent reported changes, may appear in more than one family and cause disease again and again. [36]
18. Variant causing severe infantile encephalopathy. Some DPM1 changes are linked with a very severe early brain disease with difficult seizures. [37]
19. Variant causing milder phenotype. Other variants allow some remaining function and may produce a somewhat milder course. [38] [39]
20. Variant causing dystroglycanopathy-like disease. Some DPM1 mutations mainly show muscle-disease features with congenital muscular dystrophy signs, which is still part of the same gene disorder. [40]
Symptoms
1. Global developmental delay. Many affected children are late in learning head control, sitting, standing, walking, and speech because the brain and muscles are both affected. [41] [42]
2. Motor delay. Gross motor skills are often much more delayed than expected for age. [43]
3. Hypotonia. Low muscle tone is one of the best-known signs. The baby may feel floppy and weak. [44] [45]
4. Seizures. Seizures often begin early and may be severe or hard to control. Some patients have epileptic encephalopathy. [46] [47]
5. Microcephaly. The head may be smaller than expected, or it may become progressively small over time. [48] [49]
6. Intellectual disability or learning problems. Brain involvement can affect thinking, learning, communication, and daily skills. [50]
7. Eye problems. Reported eye findings include retinopathy, nystagmus, strabismus, and optic atrophy. Vision may be poor. [51] [52]
8. Ataxia or poor balance. Some children have trouble with coordination because the cerebellum or related pathways are affected. [53] [54]
9. Peripheral neuropathy. Nerve damage outside the brain and spinal cord can cause weakness, low reflexes, or sensory problems. [55] [56]
10. Dysmorphic features. Some patients have facial or limb differences, though these are not the same in every child. [57] [58]
11. Feeding difficulty. Babies may feed poorly because of low tone, neurologic disease, and gut problems. [59]
12. Severe gastrointestinal problems. Some reports describe major gut disease, including severe enterocolitis-type illness and poor tolerance of feeds. [60] [61]
13. Muscle weakness or muscular dystrophy-like signs. Some patients show a dystroglycanopathy-type congenital muscular dystrophy picture. [62] [63]
14. Kidney or liver involvement. Not every child has this, but some case reports describe hepatic dysfunction or kidney ultrasound abnormalities. [64] [65]
15. Failure to thrive or poor growth. Because of feeding problems, neurologic disease, and multisystem illness, growth may be poor. [66] [67]
Diagnostic tests
The diagnosis usually needs a mix of clinical examination, biochemical screening, and genetic confirmation. No single bedside sign is enough. [68] [69]
1. General physical examination. The doctor checks growth, head size, tone, alertness, facial features, feeding status, and overall development. This helps raise suspicion for a multisystem genetic disease. [70]
2. Head circumference measurement. This simple exam checks for microcephaly or progressive slowing of head growth. [71] [72]
3. Developmental assessment. The clinician looks at milestones such as smiling, sitting, standing, and speech. Delay is very common in DPM1-CDG. [73] [74]
4. Neurologic examination. Tone, reflexes, strength, coordination, and seizure history are checked to understand brain, muscle, and nerve involvement. [75] [76]
5. Eye examination. A detailed eye exam can look for strabismus, nystagmus, retinopathy, or optic atrophy. [77] [78]
6. Manual muscle testing. In older infants or children, the examiner may manually assess strength to look for muscle weakness. [79]
7. Tone and posture assessment. This bedside assessment helps show hypotonia, poor head control, and floppy posture. [80] [81]
8. Coordination testing. Finger-to-nose or age-appropriate cerebellar testing can support ataxia or cerebellar dysfunction in milder patients. [82]
9. Serum transferrin isoelectric focusing. This is a key screening test for many N-glycosylation disorders. In DPM1-CDG it can show a type 1 pattern. [83] [84]
10. Alpha-1-antitrypsin isoelectric focusing. This supportive biochemical test may also show an abnormal glycosylation pattern. [85]
11. Mass spectrometry or advanced glycosylation studies. Specialized labs may use mass spectrometry or similar methods to better define the glycosylation defect. [86]
12. Basic metabolic panel and routine blood tests. These are often done to look for organ stress and rule out other metabolic diseases, though they may be normal. [87]
13. Liver function tests. Doctors may check serum transaminases and related markers if liver involvement is suspected. [88] [89]
14. Creatine kinase test. CK may help when there is muscle disease or a dystroglycanopathy-like picture. [90] [91]
15. Coagulation studies such as antithrombin III. Some patients can show coagulation abnormalities, so clotting-related tests may be useful. [92]
16. EEG. Electroencephalography records brain electrical activity and is important when seizures are present. Reported findings include severe abnormal background and multiple seizures. [93]
17. Nerve conduction studies or EMG. These electrodiagnostic tests can be used when peripheral neuropathy or muscle involvement is suspected. [94] [95]
18. Brain ultrasound in infancy. In very young babies, ultrasound may show structural brain abnormalities. One severe case had pachygyria and ventricular enlargement on ultrasound. [96]
19. Brain MRI. MRI is often used to look for brain malformations, atrophy, cerebellar changes, or other structural problems. [97] [98]
20. Molecular genetic testing of DPM1. This is the confirmatory test. Doctors may use a CDG panel, whole exome sequencing, or trio sequencing to find the disease-causing variants. [99] [100] [101]
DPM1-CDG is a very rare inherited disorder in which the body cannot do glycosylation normally because both copies of the DPM1 gene are not working well. The most important signs are developmental delay, low muscle tone, seizures, microcephaly, eye problems, and other multisystem findings. The best screening clue is an abnormal serum transferrin isoelectric focusing result, and the final diagnosis is made by genetic testing. [102] [103] [104]
Non-Pharmacological Treatments
1. Regular care by a metabolic or genetics team is important because DPM1-CDG can affect many body systems at the same time. This team usually coordinates neurology, nutrition, rehabilitation, eye care, and gastroenterology. The purpose is early problem finding. The mechanism is simple: regular review catches seizures, feeding failure, weight loss, aspiration, and developmental setbacks before they become more dangerous. [CDG review] [GeneReviews]
2. Physical therapy helps children with low muscle tone, poor balance, and delayed motor skills. The purpose is to improve posture, head control, sitting, standing, transfers, and safe movement. The mechanism is repeated guided movement that strengthens muscles, improves joint control, and supports brain-body learning. [GeneReviews] [neurology review]
3. Occupational therapy supports hand skills, daily activities, sensory regulation, and safe positioning. The purpose is to improve function in feeding, play, dressing, and communication. The mechanism is structured practice that builds fine motor control and better use of adaptive tools. [GeneReviews] [CDG review]
4. Speech and language therapy is useful even for children who are not yet speaking. The purpose is to improve communication and support oral-motor function. The mechanism includes training of swallowing, mouth movement, and use of signs, pictures, or communication devices. [GeneReviews] [nutrition review]
5. Feeding therapy can reduce choking, slow eating, and poor oral intake. The purpose is to make feeding safer and more efficient. The mechanism is texture adjustment, pacing, positioning, and swallow practice under trained supervision. [nutrition therapies] [nutrition interventions]
6. High-calorie nutrition planning is often needed because many CDG patients have failure to thrive. The purpose is to support growth and energy. The mechanism is giving enough calories, protein, and fluids in a form the child can tolerate. [nutrition therapies] [nutrition interventions]
7. Nasogastric tube feeding may be used when oral feeding is unsafe or too weak to meet needs. The purpose is short-term nutrition support. The mechanism is direct delivery of food and medicine into the stomach, which lowers the work of feeding by mouth. [GeneReviews] [nutrition therapies]
8. Gastrostomy tube feeding may be considered for long-term poor intake, aspiration risk, or severe growth failure. The purpose is reliable long-term nutrition and medicine delivery. The mechanism is bypassing exhausting or unsafe oral feeding. [GeneReviews] [nutrition interventions]
9. Anti-reflux feeding measures such as upright positioning after meals and smaller frequent feeds can help when reflux is present. The purpose is to lower vomiting, pain, and aspiration risk. The mechanism is reducing stomach backflow into the food pipe. [GeneReviews] [nutrition interventions]
10. Seizure safety planning is essential in children with epilepsy. The purpose is to reduce injury and delayed treatment during a seizure. The mechanism is caregiver training, rescue plans, timing of seizures, and fast contact with emergency services when needed. [Orphanet] [case reports]
11. Vision assessment and low-vision support are helpful because eye abnormalities have been reported in DPM1-CDG. The purpose is to detect problems such as nystagmus, strabismus, or retinal disease early. The mechanism is correction, therapy, and visual adaptation to improve function. [Orphanet] [GeneReviews]
12. Hearing assessment is useful in complex neurodevelopmental disease when speech is delayed. The purpose is to find hidden hearing loss that worsens language delay. The mechanism is early testing and hearing support when needed. [CDG review] [neurology review]
13. Orthotics and supportive seating can improve body alignment in weak or floppy children. The purpose is to make sitting, standing, and transfers safer. The mechanism is external support that reduces strain and improves positioning. [rehabilitation guidance] [GeneReviews]
14. Stretching and contracture prevention may help when movement is limited. The purpose is to keep joints flexible and reduce pain or deformity. The mechanism is regular guided range-of-motion work. [rehabilitation guidance] [neurology review]
15. Constipation care with diet, fluid, and toileting routine can be important in neurologically affected children. The purpose is easier bowel movements and less abdominal pain. The mechanism is more fiber when safe, enough fluid, and scheduled bowel habits. [nutrition interventions] [GI case]
16. Aspiration prevention includes slow feeding, safe textures, and swallow review. The purpose is to reduce pneumonia and choking. The mechanism is matching the feeding method to swallowing ability. [nutrition interventions] [GeneReviews]
17. Infection prevention matters because severe illness can destabilize fragile children. The purpose is to reduce hospitalizations and sepsis risk. The mechanism is vaccines, hand hygiene, nutrition support, and early assessment of fever. [mortality review] [case report]
18. Genetic counseling for the family explains inheritance, testing, and future pregnancy risk. The purpose is informed family planning and earlier diagnosis in relatives. The mechanism is education about autosomal recessive inheritance and test options. [genetic counseling review] [Orphanet]
19. School and developmental support plans help children reach their best function. The purpose is practical learning support and safer participation. The mechanism is special education services, therapy integration, and individualized goals. [plain language CDG framework] [CDG review]
20. Palliative and quality-of-life support may be needed in very severe disease. The purpose is comfort, feeding guidance, symptom control, and family support. The mechanism is reducing suffering and helping families make clear care decisions. [mortality review] [severe DPM1 case]
Drug Treatments
There is no FDA-approved drug that corrects DPM1-CDG itself. The medicines below are symptom-based medicines a specialist may use depending on the child’s problems. Doses in children are often age- and weight-based, so the exact dose must be set by the treating doctor. [CDG review] [treatment review]
1. Levetiracetam may be used for seizures. It is an antiseizure medicine. FDA labeling includes oral and other forms for epilepsy, including pediatric use. Doctors use it to lower abnormal electrical activity in the brain. Common side effects can include sleepiness, irritability, and behavior change. [FDA Keppra]
2. Diazepam rectal gel may be used as a rescue medicine for seizure clusters. It is a benzodiazepine. Its purpose is urgent seizure control outside the hospital. It works by increasing inhibitory brain signaling. Sleepiness and breathing suppression can occur, so it must be used exactly as prescribed. [FDA Diastat]
3. Baclofen may help painful stiffness, spasms, or increased muscle tone in selected patients. It is an antispasticity drug. It works mainly at the spinal cord level to reduce overactive muscle signals. Sleepiness, weakness, and low tone can worsen in some children, so careful supervision is needed. [FDA baclofen]
4. Proton pump inhibitors such as omeprazole may be used if the child has reflux. Their purpose is to reduce stomach acid and lessen pain or esophageal injury. The mechanism is acid suppression. Doctors choose the exact pediatric dose by age and weight. [standard supportive care]
5. Histamine-2 blockers such as famotidine may also be used for reflux in some children. Their purpose is similar to proton pump inhibitors. They lower acid production and can improve feeding comfort. [supportive GI care]
6. Polyethylene glycol 3350 may be used for constipation. It is an osmotic laxative. It pulls water into the stool, which softens stool and supports easier bowel movements. Bloating or loose stool may happen. [FDA PEG 3350]
7. Lactulose may be used when constipation is persistent. It is an osmotic laxative that helps hold water in the bowel. Its purpose is to reduce hard stools and bowel pain. [supportive GI care]
8. Glycerin suppositories may be used for short-term relief of stool retention in infants and children. Their purpose is to trigger bowel emptying when stool is stuck in the rectum. [supportive bowel care]
9. Ondansetron may be used for severe vomiting in selected situations. Its purpose is symptom control and protection from dehydration. It blocks serotonin signaling involved in nausea and vomiting. [supportive GI care]
10. Acetaminophen (paracetamol) may be used for pain or fever. Its purpose is comfort. The mechanism is central pain and fever reduction. Pediatric doses must be weight-based to avoid overdose. [general pediatric supportive care]
11. Ibuprofen may sometimes be used for pain or fever if the child is well hydrated and kidney function is acceptable. It is a nonsteroidal anti-inflammatory drug. [general supportive care]
12. Melatonin may be used for sleep disturbance in some neurologically affected children. Its purpose is to improve sleep timing and reduce caregiver burden. [neurology supportive care]
13. Clobazam or another specialist-chosen benzodiazepine may be used in some epilepsy plans. The purpose is seizure reduction. Sedation and tolerance can limit use. [epilepsy supportive care]
14. Valproate may be considered by neurologists for some seizure types, but only after careful risk review. It changes brain signaling to reduce seizures. Liver risks and other side effects require monitoring. [epilepsy supportive care]
15. Topiramate may be used in selected patients with difficult seizures. It works through several antiseizure mechanisms. Side effects can include appetite loss and sleepiness. [epilepsy supportive care]
16. Gabapentin may help some children with neuropathic discomfort or irritability related to neurologic disease, though this is symptom-based and individualized. [neurology supportive care]
17. Oral rehydration solution is not a “drug” in the usual sense, but it is a medically important treatment during diarrhea or vomiting. The purpose is to replace water and salts and prevent dehydration. [nutrition interventions]
18. Vitamin D may be prescribed when low levels or poor bone health are present. Its purpose is bone support, especially in children with low mobility or limited intake. [nutrition interventions]
19. Iron may be prescribed only if iron deficiency is proven. Its purpose is to treat iron-deficiency anemia, not DPM1-CDG itself. [nutrition interventions]
20. Multivitamin or trace-element replacement may be used when intake is poor or tube feeding plans show gaps. This is supportive nutrition, not a cure. [nutrition interventions]
Dietary Molecular Supplements
For DPM1-CDG, no supplement has proven disease-correcting benefit. Supplements are used only when a clinician identifies a deficiency or a clear nutrition need. [treatment review] [nutrition interventions]
1. Vitamin D may support bone strength.
2. Calcium may help bone mineralization when intake is low.
3. Iron may help only in confirmed iron deficiency.
4. Zinc may support growth and immunity when low.
5. Selenium may be replaced if deficient.
6. Folate may be needed in poor intake states.
7. Vitamin B12 may be used if deficient.
8. Omega-3 fatty acids may support general nutrition, though not DPM1 correction.
9. Protein supplements may help growth and muscle support.
10. Oral electrolyte supplements may help during vomiting or diarrhea. Each should be individualized and monitored by the medical team. [nutrition therapies] [nutrition interventions]
Immunity Booster, Regenerative, or Stem Cell” Drugs
At present, I could not find evidence that immune booster drugs, regenerative drugs, stem cell drugs, or stem cell transplant are established treatments for DPM1-CDG. Giving such treatment as routine care would not be evidence-based. [CDG state of the art] [treatment review]
The six safest evidence-based points are these: 1. none are approved for DPM1-CDG; 2. they should not replace supportive care; 3. experimental therapies may appear only in research settings; 4. infection prevention is better supported than “immune boosting”; 5. nutritional correction helps if deficiency exists; 6. families should ask about clinical trials rather than unproven regenerative products. [CDG state of the art] [Frontiers cohort]
Surgeries or Procedures
1. Gastrostomy tube placement may be done when long-term nutrition by mouth is unsafe or not enough. 2. Nissen fundoplication may be considered in severe reflux with aspiration in selected cases. 3. Strabismus surgery may help selected eye alignment problems. 4. Orthopedic procedures may be needed later if contractures or hip/spine problems develop from severe motor disability. 5. Airway or ENT procedures may be considered only if swallowing, breathing, or secretion problems become severe. These are not disease-curing surgeries; they are supportive procedures for complications. [GeneReviews] [Orphanet] [nutrition interventions]
Prevention Points
Because DPM1-CDG is genetic, there is no simple way to prevent the mutation after birth. Prevention focuses on complications and on future family planning. Helpful steps are: 1. genetic counseling, 2. carrier testing in parents, 3. early diagnosis in future pregnancies when desired, 4. regular seizure follow-up, 5. safe feeding review, 6. growth monitoring, 7. vision checks, 8. vaccine-based infection prevention, 9. constipation prevention, 10. fast medical review for fever, dehydration, or feeding decline. [genetic counseling review] [mortality review] [GeneReviews]
When to See Doctors
Seek urgent medical help if the child has a new seizure, seizure cluster, blue color, breathing trouble, poor feeding, repeated vomiting, dehydration, fever, unusual sleepiness, choking, weight loss, or sudden loss of skills. Regular follow-up is needed with pediatrics, neurology, genetics, nutrition, and rehabilitation even when the child seems stable. [case report] [GeneReviews] [mortality review]
What to Eat and What to Avoid
Helpful choices include 1. calorie-dense foods, 2. enough protein, 3. safe textures based on swallow ability, 4. small frequent feeds, 5. adequate fluids, 6. fiber when safe, 7. iron-rich foods if deficiency exists, 8. calcium-rich foods, 9. vitamin-D-supported nutrition, 10. dietitian-guided tube formula when needed. Avoid foods or textures that trigger choking, long fasting, poor hydration, and unproven “miracle” supplements sold online as cures for rare diseases. [nutrition therapies] [nutrition interventions]
FAQs
1. What is DPM1-CDG? It is a rare inherited glycosylation disorder caused by DPM1 mutations. [Orphanet]
2. Is it curable? There is no proven cure yet. Care is mainly supportive. [CDG review]
3. Is it inherited? Yes, usually autosomal recessive. [Orphanet] [genetic counseling review]
4. Can it cause seizures? Yes, seizures are common in reported cases. [Orphanet] [case reports]
5. Can it affect feeding? Yes, feeding difficulty and severe GI disease can occur. [GI case] [nutrition interventions]
6. Can it affect the eyes? Yes, eye abnormalities have been reported. [Orphanet] [GeneReviews]
7. How is it diagnosed? By biochemical screening such as transferrin testing in the right setting and by molecular genetic testing. [diagnosis review] [CDG review]
8. Are there disease-specific medicines? Not proven for DPM1-CDG at this time. [treatment review] [CDG state of the art]
9. Can therapy help? Yes. Physical, occupational, speech, and feeding therapies can improve function and safety. [GeneReviews]
10. Will every child be the same? No. Severity varies a lot. [case reports] [Orphanet]
11. Is tube feeding ever needed? Yes, sometimes for poor growth or unsafe swallowing. [GeneReviews] [nutrition therapies]
12. Should families use stem cell treatment? Not as routine care, because evidence is lacking for DPM1-CDG. [treatment review]
13. Can children live longer with supportive care? Good supportive care is important and may reduce complications, though prognosis depends on severity. [mortality review]
14. Is genetic counseling important? Yes, very important for recurrence risk and family planning. [genetic counseling review]
15. What is the most important next step after diagnosis? Build a multidisciplinary care plan early. [CDG review] [GeneReviews]
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: March 31, 2025.
